Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × Docetaxel × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 22 Prostatic Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 9 Lung Neoplasms 7 Stomach Neoplasms 6 Neoplasms 6 Breast Neoplasms 5 Urinary Bladder Neoplasms 4 Carcinoma, Transitional Cell 4 Prostatic Neoplasms, Castration-Resistant 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Non-Muscle Invasive Bladder Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Squamous Cell 3 Triple Negative Breast Neoplasms 2 Solid Tumors 2 Sarcoma 2 Ovarian Neoplasms 2 Oropharyngeal Neoplasms 2 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2 HER2-positive Breast Cancer 2 Advanced Solid Tumors 2 Vaccinia 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1 Small Cell Lung Carcinoma 1

Interventions

Capecitabine 4 pembrolizumab 3 Oxaliplatin 3 zolbetuximab 2 cemiplimab 2 Radiotherapy, Image-Guided 2 Radiosurgery 2 Paclitaxel 2 Nivolumab 2 Leucovorin 2 Gemcitabine 2 Fluorouracil 2 Cisplatin 2 130-nm albumin-bound paclitaxel 2 trastuzumab deruxtecan 1 tepotinib 1 repotrectinib 1 relacorilant 1 fludarabine 1 enzalutamide 1 durvalumab 1 darolutamide 1 atezolizumab 1 apalutamide 1 alpha-2'-deoxythioguanosine 1 aldesleukin 1 abiraterone 1 Valacyclovir 1 Trastuzumab 1 Taxes 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06592924 2026-04-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡